Tianfeng Securities released a research report on April 24 stating that it gave Shandong Pharmaceutical (600529.SH) a purchase rating, with a target price of 38.01 yuan. The main reasons for the rating include: 1) strong revenue growth, resonance in the borosilicate industry trends/categories, and optimism for sustainability; 2) further improvement in profitability, excellent capital structure and cash flow management. (Mainichi Keizai Shimbun)
天风证券4月24日发布研报称，给予山东药玻（600529.SH）买入评级，目标价格为38.01元。评级理由主要包括：1）收入增长强劲，中硼硅产业趋势/拓品类共振，看好持续性；2）盈利能力进一步提升，资本结构及现金流经营优异。（每日经济新闻）
Tianfeng Securities released a research report on April 24 stating that it gave Shandong Pharmaceutical (600529.SH) a purchase rating, with a target price of 38.01 yuan. The main reasons for the rating include: 1) strong revenue growth, resonance in the b
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.